GSK250502P35500
- 0.08
- 0.000.00%
GlaxoSmithKline Newsroom
FDA to Speed up AI Rollout to Accelerate Drug Reviews
GSK Met Main Goal in Liver Disease Treatment Trial
EU Regulator Finds Suicidal Thoughts as a Side Effect of Hair Loss Therapy
GSK's Liver Disease Symptom Therapy Meets Late-stage Trial's Primary Endpoint
GSK Announced Results From GLISTEN Phase 3 Trial Of Linerixibat In Adults With Cholestatic Pruritus And PBC, A Rare Autoimmune Liver Disease. The Full Data Were Presented In A Late-breaker Oral Presentation At The EASL Congress 2025
GLISTEN Phase III Trial Results Show Linerixibat Significantly Improves Cholestatic Pruritus (Relentless Itch) in Primary Biliary Cholangitis (PBC)
Daily short sale tracking: Palantir's short volume increased by 10 million, with a short sale ratio of 12%
Market Chatter: Expanded Indication for GSK, Pfizer RSV Vaccines Faces Government Review
Moderna, Pharma Stocks Fall as FDA Names Industry Critic as Top Vaccine Regulator
Unusual Options Activity: MAT, KR and Others Attract Market Bets, MAT V/OI Ratio Reaches 110.9
India Offers US Reciprocal Zero Tariffs on Steel, Auto Parts, Pharmaceutical Drugs, Bloomberg Reports
GSK Declares $0.4216 Dividend
GlaxoSmithKline (GSK) Gets a Hold From Barclays
GlaxoSmithKline To Go Ex-Dividend On May 16th, 2025 With 0.42909 USD Dividend Per Share
AlphaValue/Baader Europe Notes GSK's 'Healthy' Start to FY25 After Q1 Beat
FDA to Tighten Vaccine Approval Requirements: Reports
Trump Administration Said to Be Investing $500M on Developing Universal Vaccines
Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
Research Alert: CFRA Keeps Hold Opinion On Adss Of Gsk
GSK Plc (GSK) Q1 2025 Earnings Conference Call Transcript Summary